

		Demographics				Disease Sites			
Study	N	Age	Gender	BMI	Performance Score	Primary Site	Metastatic Site Counts	Liver Affected	Lung Affected
BICC-C	547	0.0	0.0	0.0	0.0	32.2	0.4	0.0	0.0
AVF2107g	923	0.0	0.0	0.9	0.1	0.0	0.2	0.2	0.2
N016966	2035	0.0	0.0	0.2	0.3	0.0	0.0	0.1	0.3
AVF2192g	209	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0
N9741	1416	0.1	0.0	5.4	13.7	100.0	0.0	0.0	0.0
OPTIMOX1	621	0.0	0.2	100.0	0.0	1.8	1.1	1.0	1.1
OPTIMOX2	202	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0
C97-3	226	0.0	0.0	3.1	0.0	0.0	2.7	0.0	0.0
PACCE (C249)	1053	0.0	0.0	0.1	0.0	0.0	100.0	100.0	100.0
PRIME (C203)	1183	0.0	0.0	0.3	0.2	0.0	100.0	100.0	100.0
CAIRO1	820	0.0	2.1	6.5	0.0	100.0	13.5	14.8	20.7
CAIRO2	755	0.4	0.0	2.6	0.9	2.5	7.0	7.9	12.6
CRYSTAL	1221	0.1	0.0	1.1	0.0	0.0	100.0	100.0	100.0
COIN	2445	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.0
FOCUS	2118	0.1	0.0	0.9	0.0	0.1	2.2	2.2	2.2
FOCUS2	459	0.0	0.0	6.3	0.0	0.7	1.1	1.1	1.1
03-TTD-01	342	0.0	0.0	100.0	0.0	0.0	1.2	0.0	0.0
Macro	476	0.0	0.0	0.2	0.4	0.0	100.0	100.0	100.0
AGITG (MAX)	471	0.0	0.0	1.7	0.0	0.8	0.0	0.0	0.0
HORG 99.30	283	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0
GONO	244	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0
AIO 22	474	0.0	0.0	2.5	5.5	3.8	1.9	0.0	0.0
FIRE II (CIOX)	177	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0
HORIZON II	1076	0.0	0.0	0.6	0.0	100.0	0.4	0.0	0.0
HORIZON III	1614	0.0	0.0	1.1	0.2	100.0	0.9	0.0	0.0
OPUS	344	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0
FIRE III	592	0.0	0.0	1.2	0.0	0.0	100.0	0.0	0.0
TRIBE	508	0.0	0.0	2.6	0.0	5.5	0.0	0.0	0.0

22834

- 100% missing
- >50% missing
- 30-50% missing

		Prior Treatment	Laboratory Data			
Lymph Nodes Affected	Peritoneum Affected	Prior Chemotherapy	Baseline Albumin	Baseline bilirubin	Baseline Hemoglobin	Baseline Platelets
0.0	0.0	100.0	100.0	0.7	0.7	0.5
0.2	100.0	0.0	5.2	5.2	8.5	9.8
2.8	3.3	0.0	21.4	17.0	17.7	17.5
0.0	100.0	0.0	3.3	3.3	4.3	5.7
0.0	0.0	0.0	100.0	13.8	20.8	13.7
1.1	1.1	0.3	100.0	100.0	100.0	0.6
0.0	0.0	0.5	100.0	100.0	100.0	53.5
0.0	0.0	0.0	100.0	7.5	3.5	2.7
100.0	100.0	0.0	3.1	3.1	3.4	4.0
100.0	100.0	100.0	3.7	1.4	1.3	1.4
18.5	13.7	0.1	26.3	10.4	5.9	6.3
9.0	4.2	1.9	16.7	4.8	3.0	3.2
100.0	100.0	0.0	100.0	9.7	7.8	7.5
0.0	0.0	0.0	100.0	0.4	100.0	0.5
2.2	2.3	0.3	100.0	0.5	100.0	0.8
1.1	1.1	100.0	0.4	0.2	100.0	0.0
0.0	0.0	0.0	42.1	2.3	0.9	0.3
100.0	100.0	0.0	25.4	13.7	0.2	0.2
0.0	0.0	0.0	0.0	0.0	0.2	0.0
0.0	0.0	0.0	100.0	100.0	6.7	5.7
0.0	0.0	0.0	100.0	100.0	100.0	100.0
0.0	0.0	0.6	100.0	9.1	9.7	4.2
0.0	0.0	0.0	100.0	10.2	2.3	1.7
0.0	0.0	0.0	100.0	0.0	0.0	0.0
0.0	0.0	0.0	100.0	0.7	0.3	0.4
0.0	0.0	0.0	71.5	2.0	1.7	2.0
100.0	0.0	0.8	100.0	100.0	100.0	100.0
0.0	100.0	0.0	22.0	5.3	1.4	1.0

Baseline White Blood Cells	Baseline Neutrophil Counts	Biomarker	
		KRAS Status	BRAF Status
0.7	10.2	100.0	100.0
8.3	8.3	100.0	100.0
17.5	25.1	100.0	100.0
4.3	4.3	100.0	100.0
100.0	13.8	100.0	100.0
99.5	100.0	100.0	100.0
54.0	100.0	100.0	100.0
100.0	3.5	100.0	100.0
3.4	3.4	16.9	100.0
1.2	1.3	7.4	100.0
28.4	100.0	55.9	100.0
2.9	22.5	29.9	31.4
7.5	8.7	12.9	18.0
0.3	0.3	20.4	20.5
0.8	100.0	100.0	100.0
0.0	3.3	100.0	100.0
0.3	0.3	100.0	100.0
0.0	25.8	17.6	100.0
100.0	0.0	100.0	100.0
7.4	4.9	88.0	88.0
4.1	100.0	100.0	100.0
4.2	86.3	57.8	100.0
1.7	29.9	17.5	22.6
0.0	0.5	100.0	100.0
0.3	0.6	100.0	100.0
1.7	2.9	6.7	7.6
100.0	100.0	0.0	18.8
0.8	2.2	22.6	22.6